Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, surged to hit its upper circuit limit on 18 Mar 2026, closing at ₹36.60 with a robust gain of 4.99% on the day. This sharp rally was driven by intense buying pressure, a significant rise in delivery volumes, and a notable gap-up opening, signalling renewed investor interest despite the company’s recent downgrade to a Sell rating by MarketsMOJO.

Fischer Medical Ventures Ltd surged to its upper circuit limit on 17 Mar 2026, closing at ₹34.86, marking a maximum daily gain of 5.0%. The stock demonstrated robust buying interest, outperforming its sector and reversing a three-day losing streak despite trading below key moving averages. However, regulatory restrictions have frozen further trading, leaving significant unfilled demand in the market.

Fischer Medical Ventures Ltd has seen its investment rating downgraded from Hold to Sell as of 16 March 2026, driven primarily by deteriorating technical indicators, expensive valuation metrics, and subdued financial trends despite recent strong quarterly results. The company’s Mojo Score now stands at 47.0, reflecting a cautious stance amid ongoing market challenges and weak price momentum.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, has touched a new 52-week low of Rs.32.92 as of 16 Mar 2026, marking a significant decline amid broader market pressures and company-specific performance factors.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a bearish trend. Despite a modest upgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical parameters suggest caution for investors amid ongoing volatility.

Fischer Medical Ventures Ltd has seen its investment rating upgraded from Sell to Hold as of 11 March 2026, reflecting a nuanced assessment of its financial performance, valuation metrics, and market participation. Despite strong quarterly results and a debt-free balance sheet, concerns over management efficiency and valuation remain, prompting a cautious stance from analysts.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, witnessed intense selling pressure on 5 Mar 2026, hitting its lower circuit limit and closing at ₹35.12. The stock declined by 3.79% on the day, underperforming both its sector and the broader market, as panic selling and unfilled supply weighed heavily on investor sentiment.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, witnessed intense selling pressure on 2 Mar 2026, culminating in the stock hitting its lower circuit limit. The share price plunged by 4.33% on the day, marking a continuation of a five-day losing streak that has eroded over 10% of its value, signalling mounting investor concerns and a deteriorating market sentiment.

Fischer Medical Ventures Ltd has seen its investment rating downgraded from Hold to Sell following a comprehensive reassessment of its technical indicators, valuation metrics, financial trends, and overall quality. The downgrade reflects growing concerns over the company’s deteriorating price momentum, expensive valuation, subdued profitability, and weakening institutional participation, signalling caution for investors amid challenging market conditions.

Fischer Medical Ventures Ltd, a key player in the Commodity Chemicals sector, has experienced a notable shift in technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 Feb 2026. The stock’s price has declined by 2.41% on 26 Feb 2026, reflecting growing bearish sentiment amid mixed technical signals and a challenging market backdrop.

Fischer Medical Ventures Ltd is rated Hold by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the latest insights into its performance and outlook.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, witnessed a sharp decline on 10 Feb 2026, hitting its lower circuit limit with a maximum daily loss of 4.98%. The stock closed at ₹43.5, down ₹2.18 from the previous close, reflecting intense selling pressure and panic among investors despite recent gains.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, surged to hit its upper circuit limit on 6 Feb 2026, propelled by robust buying interest and sustained investor enthusiasm. The stock closed at ₹44.09, marking a maximum daily gain of 4.99%, significantly outperforming its sector and the broader market indices.

Fischer Medical Ventures Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement in its technical indicators and financial performance despite ongoing valuation concerns and management efficiency challenges. The upgrade, effective from 4 February 2026, is driven primarily by a shift in technical trends and steady quarterly financial results, signalling cautious optimism among analysts.

Fischer Medical Ventures Ltd has experienced a notable shift in its technical parameters, signalling a subtle change in price momentum despite a complex mix of bullish and bearish indicators. The stock’s recent 5.00% day gain to ₹40.35, coupled with an upgrade in its Mojo Grade from Sell to Hold, highlights evolving market sentiment amid a challenging commodity chemicals sector backdrop.